A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2018
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms BIBW 2992 ORL
- 20 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2016 Planned End Date changed from 1 Sep 2019 to 1 Sep 2021 as reported by ClinicalTrials.gov record.
- 17 Feb 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2018 as reported by ClinicalTrials.gov record.